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Plasma aminothiol oxidation in chronic hemodialysis patients
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Plasma aminothiol oxidation in chronic hemodialysis patients. Several important aminothiols, including homocys-
Background. Plasma aminothiols, including homocysteine, teine and cysteine, are retained as solutes in higher quan-
cysteine, and glutathione, function as an important extracellu- tities in uremic patients than in healthy subjects and arelar redox system. We examined the plasma aminothiol concen-
candidates for uremic toxins [18–27]. Both homocysteinetration and redox status in ten chronic hemodialysis patients
and cysteine can promote atherogenesis by virtue of theircompared to ten age-matched healthy subjects.
Methods. Plasma levels of reduced, free oxidized, and pro- effect on endothelial function, vascular smooth muscle
tein-bound homocysteine, cysteine, cysteinylglycine, and gluta- cell activation, and hemostatic activation [28–34]. Alter-
thione were determined using high-pressure liquid chromatog- ations in plasma homocysteine and cysteine concentra-raphy (HPLC).
tions have been associated in numerous clinical studiesResults. Total plasma homocysteine, cysteine, and cysteinyl-
with the development of vascular disease [35–38]. Inglycine levels were significantly elevated in hemodialysis pa-
tients before dialysis compared to healthy subjects. Total contrast, the aminothiol glutathione and its metabolite,
plasma concentration of cysteine and homocysteine signifi- cysteinylglycine, have important antioxidative and likely
cantly decreased after hemodialysis. The ratio of free oxidized
anti-atherogenic properties [39–41].to free reduced homocysteine, cysteine, cysteinylglycine, and
To date, few studies have specifically examined bothglutathione were each significantly elevated before dialysis
compared to healthy subjects, and decreased significantly by the plasma concentration and the redox status of these
the end of dialysis. The free oxidized to reduced ratio of cyste- aminothiols in uremic patients. Furthermore, the effects
ine and homocysteine were also significantly correlated with of hemodialysis on the redox status (for example, the
total plasma concentrations.
ratio of oxidized to reduced molecular species) of plasmaConclusions. Plasma aminothiols are excessively oxidized in
aminothiols have not been investigated. In order to ex-uremia, while the hemodialysis procedure is restorative of re-
dox status. Oxidized aminothiols are candidate uremic toxins. amine whether increased plasma thiol oxidation in ure-
mic patients is restricted to protein-associated thiol groups
[15] or is a more generalized oxidative phenomena, we
Increased oxidant stress has been implicated in the investigated the redox status of the major plasma amino-
development of atherogenesis and cardiovascular com- thiols in patients receiving chronic hemodialysis therapy
plications for patients receiving chronic hemodialysis compared to healthy subjects. We further examined the
therapy [1–14]. An important manifestation of oxidative effects of the hemodialysis procedure on both the concen-
stress in uremic patients is an increase in the oxidation tration and the redox status of plasma aminothiols.
of thiol groups in plasma proteins, a process that can be
modified by dialysis therapy [15]. In addition to plasma
METHODSprotein-associated thiol groups, there are also low-molec-
Patient characteristicsular-weight thiol-containing compounds in the plasma
(known as aminothiols) that are largely derived from Ten patients receiving chronic maintenance hemodial-
sulfur-containing amino acids (Fig. 1). Aminothiols have ysis were compared to ten age-matched healthy controls.
a critical function as intracellular redox buffers and are The mean age of patients and healthy controls was 43
also increasingly recognized as constituting an important years (range 32 to 53 years) and 46 years (range 33 to
extracellular redox system [16, 17]. 56 years), respectively. The etiology of end-stage renal
disease (ESRD) was diabetic nephropathy in two pa-
tients, polycystic kidney disease in three patients, com-Key words: uremia, end-stage renal disease, oxidant stress, homocys-
teine, cysteine, glutathione, extracellular redox system, uremic toxin. plications of pregnancy in one patient, membranous
nephropathy in one patient, and proliferative glomerulo-Received for publication June 14, 2001
nephritis in one patient The etiology was unknown inand in revised form August 28, 2001
Accepted for publication September 18, 2001 two patients. Blood was drawn from patients just prior
to dialysis after access cannulation and from efferent 2002 by the International Society of Nephrology
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Fig. 1. Aminothiol synthesis and degradation pathways
dialyzer lines at the end of treatment. The dialysis pre- Sample collection
scription for all patients consisted of a treatment time For each sample, blood was drawn into three 5 mL
of 240 minutes with the use of a high-flux polysulfone Vacutainer tubes (Becton-Dickinson, Franklin Lakes,
dialyzer (F80; Fresenius Medical Care, Lexington, MA, NJ, USA) containing heparin as an anticoagulant and
USA). Prescribed blood flow was 400 mL/min with a either mBrB, NEM, or no additive. All tubes were imme-
dialysate flow of 800 mL/min. The mean  SEM urea diately centrifuged at 10,000  g for one minute at room
reduction ratio for patients in this study was 72  2. In temperature to remove cells and platelets. From the dif-
all cases, heparin was used as a standard anticoagulant. ferent plasma preparations, aliquots were removed and
treated to determine the various thiol components. Pre-All subjects gave informed consent and the Institutional
pared samples were stored in the dark at 4C and ana-Review Board at the Maine Medical Center approved
lyzed within six hours.all study procedures.
Sample preparation for determination of the variousReagents
thiol componentsN-ethylmalemide (NEM), N-ethylmorpholine, dithi-
Total, reduced, free oxidized, and protein-bound formsoerythritol (DTE), glutathione (GSH), homocysteine
of the plasma aminothiols were prepared and measured(Hcy), cysteinylglycine (Cys-Gly), cysteine (Cys), 5-sul-
according to the method of Mansoor, Svardal, and Ue-fosalicylic acid (SSA), and octanol were obtained from
land [42]. Selective determination of each redox speciesSigma Chemical Co. (St. Louis, MO, USA). Monobro-
was accomplished by varying the order of disulfide reduc-mobimane (mBrB) was purchased from Calbiochem (La
tion with NaBH4, protein precipitation, and derivatiza-Jolla, CA, USA) as Thiolyte Reagent. Dimethyl sulfox-
tion. In each protocol, the resulting free sulfhydryl
ide (DMSO), hydrogen bromide (HBr), sodium borohy- groups were derivatized with mBrB, forming a fluores-
dride (NaBH4), and tetrabutylammonium dihydrogen- cent thiol-bimane adduct. These compounds were sepa-
phosphate were obtained from Aldrich (Milwaukee, WI, rated and quantitated by reversed-phase HPLC. Octanol
USA). Perchloric acid and acetic acid were obtained from (2 L) was added to the samples prior to reduction to
JT Baker (Phillipsburg, NJ, USA). Acetonitrile (ACN) reduce foaming.
and high-pressure liquid chromatography (HPLC)–grade
Total plasma thiol component determinationwater were obtained from Fisher Scientific (Pittsburgh,
PA, USA). Octanol (2 L) and 30 L of 2 mmol/L NaBH4 in 0.05
Solution B was 65% DMSO and 35% water (vol/vol) mol/L NaOH were added to 30 L of untreated plasma.
Plasma proteins were then precipitated by adding 60 Lcontaining 51 mmol/L NaCl and 140 mmol/L HBr.
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of 20% sulfosalicylic acid (SSA) containing 100 mol/L for quantitation were prepared by adding known amounts
of cysteine, cysteinylglycine, homocysteine, or glutathi-DTE. After allowing for the release of gas, precipitated
protein was removed by centrifugation. Supernatant (60 one to 5% SSA containing 50 mol/L DTE. All standard
samples were processed using the protocol for total thiolL) was derivatized by adding 30L of 1.4 mol/L NaBH4
in 0.05 mol/L NaOH, 130 L of solution B, 50 L 1 components.
mol/L N-ethylmorpholine (pH 9), and 10 L of 20
Chromatographymmol/L mBrB in 100% acetonitrile. After a ten-minute
incubation at room temperature in the dark, 20 L of Prior to injection, all samples were filtered using .2 m
polyvinyl idene difluoride (PVDF) Micro-Spin centri-1.06 mol/L perchloric acid was added.
fuge filters (Alltech Associates, Inc., Deerfield, IL, USA).
Free oxidized plasma thiol component determination Aliquots (25L) were manually injected onto a Hypersil
ODS (C18) analytical column (3 m; 4.6  150 mm; Wa-A combination of 55 L 50% SSA with 500 mol/L
DTE was added to 500L NEM-treated plasma. Precipi- ters, Milford, MA, USA). The temperature was 25C
and the flow rate 1.5 mL/min. Elution solvent A was 10tated protein was removed by centrifugation. Superna-
tant (30 L) was derivatized by adding 2 L octanol, 30 mmol tetrabutylammonium phosphate and 2.5 mL acetic
acid, diluted to 1 L with HPLC-grade water, pH adjustedL 1.4 mol/L NaBH4 in 0.05 mmol/L NaOH, 160 L
solution B, 50 L 1 mol/L N-ethylmorpholine (pH 9), to 3.4 with 2 mol/L NaOH. Solvent B was 200 mL ACN,
10 mmol tetrabutylammonium phosphate and 2.5 mLand 10 L 20 mmol/L mBrB in 100% acetonitrile. After
a ten-minute incubation at room temperature in the dark, acetic acid, diluted to 1 L with HPLC grade water, pH
adjusted to 3.4 with 2 mol/L NaOH. Solvent C was 75%20 L of 1.06 mol/L perchloric acid was added.
ACN. The elution profile was as follows: 0 to 13 minutes,
Protein-bound plasma thiol component determination 6 to 22% solvent B; 13.1 to 25 minutes, 22 to 40% solvent
B; 25.1 to 30 minutes, 40 to 75% solvent B. After eachA combination of 150 L 5% SSA with 50 mol/L
DTE was added to 30 L untreated plasma. Following run, the column was washed for five minutes with solvent
C to remove late-eluting fluorescent material. (An in-protein precipitation and centrifugation, the supernatant
was discarded. To the pellet, 30 L of 2 mol/L NaBH4 in creased amount of this late-eluting fluorescent material
was found in all protein-bound and some free oxidized0.05 mol/L sodium hydroxide was added. The dissolved
pellet was derivatized by adding 30 L 40% SSA with samples of hemodialysis patients. This material made it
difficult to clearly resolve the glutathione peak. There-100mol/L DTE, 30L 1.4 NaBH4 in 0.05 mol/L NaOH,
130 L solution B, 50 L in 1 mol/L N-ethylmorpholine fore, data on protein bound glutathione was omitted
from final analysis.) As the acetonitrile concentration in(pH 9), and 10L 20 mmol/L mBrB in 100% acetonitrile.
After a 10-minute incubation at room temperature in the column solvent was increased, the bimane derivatives
of the aminothiols were eluted and detected by an in-the dark, 20 L of 1.06 mol/L perchloric acid was added.
line fluorescence detector (excitation 400 nm, emission
Reduced plasma thiol component determination 475 nm). The retention times for the bimane derivatives
of cysteine, cysteinylglycine, homocysteine, and glutathi-A combination of 55 L 50% 5-sulfosalicylic acid with
500 mol/L DTE was added to 500 L mBrB-treated one were 7.0, 9.0, 12.5, and 32.2 minutes, respectively
(Fig. 2). Compounds were identified by their retentionplasma. Precipitated protein was removed by centrifuga-
tion. Supernatant (30 L) was treated with 2 L octanol, time and co-elution with derivatized aminothiol stan-
dards.30 L 5% SSA with 5 mol/L DTE, 160 L distilled
water, 50 L of 1 mol/L N-ethylmorpholine (pH 9), and
Instrumentation10L ACN to mimic the derivatization procedure. After
a 10-minute incubation at room temperature in the dark, A Waters 626 system coupled to a Waters 474 fluores-
cence detector was used. Plotting and peak integration20 L of 1.06 mol/L perchloric acid was added.
Derivatized samples were stored in the dark at 4C were performed using Waters Millennium32 software.
and analyzed within six hours of preparation.
Total plasma protein-free sulfhydryl
group determinationStandards and calibration curves
Standard solutions of 800mol/L cysteine, 100mol/L Free sulfhydryl groups were assayed as previously de-
scribed [15]. Blood was drawn into a Vacutainer tubecysteinylglycine, 40 mol/L homocysteine, and 40mol/L
glutathione were prepared in 5% SSA containing 50 containing ethylenediaminetetraacetic acid (EDTA),
centrifuged at 1700  g for 15 minutes to obtain plasma.mol/L DTE. Equal volumes of each standard were
mixed, giving a final standard containing 200 mol/L A buffer (1 mL) containing 0.1 mol/L Tris, 10 mmol/L
EDTA (pH 8.2) and 50 L plasma were added to cu-cysteine, 25 mol/L cysteinylglycine, 10 mol/L homo-
cysteine, and 10 mol/L glutathione. Calibration curves vettes, followed by 50 L 10 mmol/L 55dithio-bis (2-
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Fig. 2. Representative high-performance liq-
uid chromatograms. (A) Authentic standards.
(B) Sample from healthy subject
nitro benzoic acid) (DTNB) in methanol. Blanks were ples. For linear regression analyses, Pearson correlation
coefficients are given with accompanying P values.run for each sample, prepared as above, with the excep-
tion that there was no DTNB in the methanol. Following
incubation for 15 minutes at room temperature, sample
RESULTSabsorbance was read at 412 nm on a lambda-2 spectro-
Total plasma aminothiols in hemodialysis patientsphotometer (Perkin Elmer, Norwalk, CT, USA). Sample
and healthy subjectsand reagent blanks were also subtracted. The concentra-
tion of sulfhydryl groups was determined using the TNB Total plasma concentrations of the aminothiols cyste-
molar extinction coefficient of 14,100 mol/L1 · cm1, ine, homocysteine, cysteinylglycine, and glutathione in
and results were reported as micromoles per liter. The patients before and after hemodialysis compared to age-
coefficient of variation for this assay was 2.7%. matched healthy subjects are depicted in Figure 3. There
was a significant increase in total plasma cysteine (478 
Data analysis and statistics 16 mol/L vs. 372  13 mol/L, P  0.0001) in patients
before dialysis compared to healthy subjects. Similarly,Results are expressed as mean  SEM. Total values
represent the sum of reduced, free oxidized and protein- there was an increase in total plasma homocysteine (41
5 mol/L vs. 14  1 mol/L, P 	 0.0002) and cysteinyl-bound values. For expressions of aminothiol ratios, val-
ues were calculated prior to statistical analyses. Unpaired glycine (77  6 mol/L vs. 56  6 mol/L, P 	 0.02)
in patients before dialysis versus healthy subjects. InStudent t tests (assuming equal or unequal variance, de-
pending on the results of an f test) evaluated the signifi- contrast, there were no significant differences in total
plasma glutathione concentration between patients be-cance of differences between healthy subjects and chron-
ic hemodialysis patients. A two-tailed paired t test was fore dialysis and healthy subjects. At the end of the
dialysis session, the total plasma concentrations of homo-performed on data comparing pre- and post-dialysis sam-
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in uremic patients and the hemodialysis procedure had
a restorative effect on redox balance.
To determine the importance of total plasma concen-
trations of plasma aminothiols on redox status, total
plasma levels and the ratio of free oxidized to free re-
duced homocysteine, cysteine, cysteinylglycine, and glut-
athione were compared (Fig. 6). Figure 6 A and B
demonstrate that for homocysteine and cysteine, there
was a positive relationship between total plasma concen-
tration and the redox ratio of free aminothiols (R 	 0.60
for homocysteine, P 	 0.005; R 	 0.68 for cysteine, P 
0.001). In contrast, there was no clear-cut relationshipFig. 3. Total plasma aminothiol concentration in hemodialysis patients
before () and () after dialysis, and age-matched healthy subjects between total plasma concentration and the redox ratio
( ). N 	 10 hemodialysis patients and healthy subjects for cysteine, of free glutathione (Fig. 6D). To further clarify the rela-
homocysteine, and cysteinylglycine (Cys-Gly). N 	 5 for glutathione
tionship between total plasma aminothiol concentrationin hemodialysis patients. *P  0.02 vs. before hemodialysis
and redox status, the concentration of free oxidized and
total plasma homocysteine, cysteine, cysteinylglycine,
and glutathione were compared (Fig. 7). Figure 7 A and
B demonstrate a striking positive relationship between
cysteine and cysteine were significantly lower than before total plasma cysteine, homocysteine, and cysteinylglycine
dialysis, while there was no significant change in glutathi- concentration and their respective concentrations of the
one or cysteinylglycine concentrations. free oxidized aminothiol.
The relationships between total plasma concentrations
of aminothiols in both healthy subjects and uremic pa- Protein binding of aminothiols in patients with uremia
tients are illustrated in Figure 4. Figure 4A demonstrates In addition to oxidation of free plasma aminothiols,
a significant positive correlation between total plasma the extent to which oxidized aminothiols are protein-
cysteine and homocysteine concentrations, particularly bound was examined in both hemodialysis patients and
in hemodialysis patients before and after dialysis (R 	 healthy subjects (Fig. 8). The ratio of free to protein-
0.81; P	 1 105). In contrast, there were no significant bound cysteine and homocysteine but not cysteinylgly-
positive correlations between plasma total homocysteine cine was higher in patients with uremia before dialysis
and cysteine concentrations and plasma cysteinylglycine compared to healthy subjects. The extent of protein bind-
concentrations in hemodialysis patients or healthy sub- ing of glutathione could not be determined due to inabil-
jects (Fig. 4 B–F). These data indicate that there is a ity to resolve this peak in protein-containing fractions,
positive relationship between the extent of hyperhomo- a phenomenon that has been observed by other investi-
cysteinemia and hypercysteinemia, but not between gators [43]. Of note, the hemodialysis procedure resulted
other aminothiols in patients with uremia. in a significant decrease in the free to protein-bound ratio
of homocysteine, cysteine, and cysteinylglycine. These
Increased oxidation of plasma aminothiols in hemodialysis results suggest that oxidized aminothiols in hemodialysis
patients compared to healthy subjects patients are less likely to bind to plasma protein than in
The plasma aminothiols constitute a complex of free healthy subjects, perhaps due to an increased saturation
reduced compounds, free oxidized compounds, and oxi- of plasma protein ligands for aminothiols. The hemodialy-
dized protein-bound compounds. To compare the redox sis procedure also proportionately cleared more free oxi-
status of plasma aminothiols in hemodialysis patients dized aminothiols compared to protein-bound aminothi-
and healthy subjects, we first compared the ratio of free ols, as would be expected for any solute given the pore
oxidized and free reduced cysteine, homocysteine, cystei- size of conventional high-flux hemodialysis membranes.
nylglycine, and glutathione in healthy subjects and hemo- To further examine the hypothesis that the ratio of
dialysis patients before and after dialysis (Fig. 5). Of free to protein-bound plasma aminothiols may be altered
note, all four free plasma aminothiols were more oxi- due to relative saturation of available protein binding
dized in hemodialysis patients compared to healthy sub- groups, we compared the slopes of protein-bound to
jects. For all plasma aminothiols, the hemodialysis proce- total plasma homocysteine, cysteine and cysteinylgly-
dure resulted in a significant change in the free oxidized cine, respectively (Fig. 9). Figure 9A demonstrates that
to free reduced ratio toward a ratio similar to those the slope (0.31) was different than the slopes for homo-
seen in healthy subjects. Thus, there was a generalized cysteine (0.74) and cysteinylglycine (0.74). Thus, at high
plasma total cysteine concentrations, protein binding ofalteration in the redox status of amino acid thiol groups
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Fig. 4. Relationships between total plasma concentrations of aminothiols in healthy subjects () and hemodialysis patients pre- () and post-
() dialysis. N 	 10 hemodialysis patients and healthy subjects for cysteine, homocysteine, and cysteinylglycine (Cys-Gly). N 	 5 for glutathione
in hemodialysis patients. R and P values were calculated for all hemodialysis patient samples.
oxidized cysteine may be relatively inhibited due to satu- ratio of protein-bound aminothiols to available plasma
thiol compared to healthy subjects (1.01 0.07 vs. 0.61ration.
0.05; P  0.001). In comparison, the ratio of protein-
bound aminothiols to available plasma protein free thiol
Plasma protein thiol redox status in patients groups at the end of the dialysis procedure was signifi-
with uremia and healthy subjects cantly different than before hemodialysis (0.63  0.06
Since protein thiols quantitatively constitute the major vs. 1.01  0.07, P 	 0.002) and similar to the ratio seen
source of antioxidant potential in the plasma [15, 44], the in healthy subjects. These results clearly demonstrate a
extent to which protein-associated thiols are oxidatively similar pattern of altered redox status of the plasma
conjugated to aminothiols was investigated (Fig. 10). protein thiol pool (similar to the free aminothiol pool)
in uremic subjects before hemodialysis compared toHemodialyzed uremic subjects had a significantly higher
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patients. While intracellular homocysteine is kept at a
low concentration and likely occurs in the reduced form,
in extracellular fluids such as plasma, homocysteine is
predominantly oxidized, either as a mixed disulfide or
as a protein-bound disulfide with albumin.
The present study demonstrated that in uremic sub-
jects, total plasma concentrations of homocysteine and
cysteine were elevated before dialysis compared to
healthy subjects, an observation similar to several previ-
ous reports. In addition, the present study demonstrated
a correlation between serum homocysteine and serum
Fig. 5. Ratio of free oxidized to reduced aminothiols in healthy subjects cysteine levels in hemodialysis patients. Since the metab-
( ) and hemodialysis patients before () and after () dialysis. N 	
olism of homocysteine via the transsulfuration pathway10 hemodialysis patients and healthy subjects for cysteine, homocys-
teine, and cysteinylglycine (Cys-Gly). N	 5 for glutathione in hemodial- may account for up to 50% of plasma cysteine levels,
ysis patients. *P  0.05 vs. before hemodialysis this correlation is not surprising. Though not as well
studied as homocysteine as a cardiovascular risk factor,
the potential vascular toxicity of cysteine has recently
been emphasized. In patients with cardiovascular dis-healthy subjects, which was restored to levels similar to
ease, both free and protein-bound cysteine levels arehealthy subjects at the end of the dialysis procedure.
higher in the plasma of patients compared to healthy
subjects [48]. In vitro, auto-oxidation of cysteine occurs
DISCUSSION more readily than homocysteine, thereby generating re-
active oxygen species that can, by oxidation, modify low-Patients with ESRD on hemodialysis therapy experi-
ence accelerated atherogenesis as evidenced by exces- density lipoprotein [49]. Of note, a recent study demon-
strated that auto-oxidation of homocysteine can be dra-sively high cardiovascular mortality. Recent studies dem-
onstrate that even after adjustment for age, race, gender, matically accelerated by the presence of either cysteine
or cystine [50]. It also has been demonstrated that cyste-and the presence of diabetes, cardiovascular mortality
is 10- to 20-fold higher than in the general population ine, and not homocysteine, leads to increased reactive
oxygen species production by vascular smooth muscle[45]. Furthermore, risk factors such as hypertension and
hypercholesterolemia, which are predictive of cardiovas- cells [30, 51]. The potential synergistic toxicity of hyper-
homocysteinemia and hypercysteinemia in patients withcular morbidity and mortality in the general population,
are not as predictive of cardiovascular complications in chronic kidney disease has not been well explored and
likely will be a subject for further investigation.patients with chronic kidney disease, suggesting that pro-
cesses related to uremia may contribute in unique ways In this study, we did not observe a significant differ-
ence in total plasma glutathione levels in uremic patientsto cardiovascular complications in this patient popula-
tion [9, 46]. A major focus of current efforts to lower prior to dialysis compared to healthy subjects. A recent
study, also using HPLC methodology, demonstrated sim-cardiovascular complications in uremic patients is a bet-
ter understanding of the contributions of solute retained ilar results in a study of nine hemodialysis patients [52].
Previous studies of total plasma glutathione levels inin uremia to cardiovascular toxicity.
Patients with chronic kidney disease, particularly those hemodialysis patients have yielded mixed results, with
some studies demonstrating elevated plasma levels andrequiring chronic dialysis therapy, have been reported
to have numerous disturbances in the metabolism of other studies demonstrating normal or decreased levels
compared to healthy subjects [13, 24, 52–54]. These dis-plasma sulfur amino acids [23, 25]. In recent years, much
attention has been focused on elevated total plasma crepancies are likely due to the fact that glutathione is
primarily an intracellular antioxidant. Thus, even mini-homocysteine levels in uremic patients as a potential
risk factor for early-onset cardiovascular disease [18–27]. mal degrees of hemolysis during plasma sampling will
artifactually elevate plasma glutathione levels. As anHyperhomocysteinemia is extremely prevalent in this
patient population and is not entirely normalized by sup- example, Suliman et al recently compared plasma and
erythrocyte glutathione levels in hemodialysis patientsplementation with vitamin B6 and folic acid. Homocys-
teine, once formed, is either salvaged to methionine by and demonstrated that erythrocyte levels are approxi-
mately 700-fold higher than plasma levels [24].remethylation, or is condensed with serine to form cysta-
thionine, which is further catabolized to cysteine in the To elucidate the in vivo redox status of aminothiols,
it is important to recognize that each of these plasmatranssulfuration pathway (Fig. 1) [47]. Abnormalities in
both remethylation and transulfuration pathways of thiols can exist as free reduced compounds, mixed disul-
fides, and as mixed disulfides with plasma protein; thus,homocysteine metabolism have been described in uremic
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Fig. 6. Comparison of total plasma concentrations and the ratio of free oxidized and reduced aminothiols in healthy subjects () and uremic
patients before () and after () dialysis. N	 10 hemodialysis patients and healthy subjects for cysteine (A), homocysteine (B), and cysteinylglycine
(Cys-Gly; C). N 	 5 for glutathione (D) in hemodialysis patients. R and P values were calculated for all hemodialysis patient samples.
their interrelated pathways are highly complex [43]. This reduced species in plasma by collecting blood directly
into tubes containing sulfhydryl-reactive agents such ascomplexity is increased by interrelations in the synthesis
and metabolism of the individual aminothiols. Thus, monobromobimane [50] or N-ethylmaleimide and then
immediately removing blood cells. This methodologywhile homocysteine can be metabolized to cysteine, cys-
teine is a precursor of glutathione. Catalysis of glutathi- previously has been used to examine changes in the re-
dox status of aminothiols in healthy subjects during me-one by gamma glutamyl transpeptidase (located on the
external surface of cell membranes and found in the thionine or homocysteine loading, and in patients with
hyperhomocysteinemia due to cobalamin deficiency andplasma) results in the formation of cysteinylglycine.
In the past, several analytic approaches were used to homocysteinuria [57–60]. Recently, an alternative strat-
egy to measure the redox status of aminothiols in humanmeasure aminothiol oxidation. Glutathione has been
analyzed using a variety of spectrophotometric, chroma- plasma has been developed by Andersson et al [52]. In
this system, the reduced sulfhydryl species in the plasmatographic, and enzymatic techniques. The disulfides
formed by low-molecular-weight thiols have been ana- fraction were protected against in vitro oxidation by
adding sulfosalicylic acid, thereby lowering pH. Underlyzed by chromatography, by enzymatic assays, and by
HPLC. Recently, methodology employing gas chroma- optimal sample processing, both methodologies obtain
similar values, although they have not been simultane-tography-mass spectroscopy, has been employed to ana-
lyze reduced plasma homocysteine concentrations [55]. ously employed in the same study.
A major finding in our present study is that all ofA common feature of many existing methods is their
inability to simultaneously quantify the oxidized and re- the important free plasma aminothiols (homocysteine,
cysteine, cysteinylglycine, glutathione) are more oxi-duced form of all the important aminothiols in biological
systems. dized in uremic subjects before dialysis compared to
healthy subjects. Furthermore, the dialysis procedure hasThe HPLC methodology utilized in this study was
developed by Mansoor, Svardal, and Ueland, and col- a beneficial effect in improving the redox status of each
of the free plasma aminothiols, approaching levels byleagues [42, 56–60] The assays are based on trapping the
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Fig. 7. Comparison of total plasma aminothiol concentrations and their respective free oxidized concentration in healthy subjects () and uremic
patients before () and after () dialysis. N 	 10 hemodialysis patients and healthy subjects for cysteine (A), homocysteine (B), cysteinylglycine
(Cys-Gly; C). N 	 5 for glutathione (D) in hemodialysis patients. R and P values calculated for all hemodialysis patient samples.
advanced to explain the development of vascular disease
in diabetes mellitus [61]. These findings suggest that
correcting the metabolic derangements leading to thiol
oxidation in uremia may be an important approach to
reducing cardiovascular complications in this patient
population.
Previous studies that systematically examined amino-
thiol oxidation in uremic patients and the effects of the
hemodialysis procedure have been sparse. Andersson
and colleagues have used HPLC methodology with acidi-Fig. 8. Ratio of free to protein bound aminothiols in healthy subjects
( ) and hemodialysis patients before () and after () dialysis. N 	 fied plasma to examine the redox status of aminothiols in
10 patients in each group. *P  0.05 vs. before hemodialysis. uremic patients [21, 52]. In their most recent publication,
nine uremic patients on dialysis therapy were noted to
have elevations in total plasma concentrations of cyste-
ine, cysteinylglycine, and homocysteine (but not glutathi-the end of the dialysis procedure observed in healthy
one) compared with healthy subjects [52]. These findingssubjects. There is concordance between the results ob-
are in accordance with the results of our present study.served in this study and our previous work examining
These investigators also noted a lower reduced to totalplasma protein–associated thiol oxidation [15]. This sug-
plasma concentration of cysteine, glutathione, cysteinyl-gests that a generalized derangement in thiol redox status
glycine, and homocysteine in uremic patients comparedexists in uremia that tends to be ameliorated by dialysis.
to healthy subjects, findings that are a different measureThis uremia-associated “thiol stress” is quantitatively the
but conceptually consistent with our present study. Thesemajor demonstrable alteration in plasma redox chemis-
authors did not directly measure the ratio of free reducedtry induced by the uremic state. Furthermore, the extent
to free oxidized aminothiols, nor did they examine theof homocysteine, cysteine, and cysteinylglycine oxidation
effect of hemodialysis on aminothiol concentration oris related to total plasma concentrations. The concentra-
redox status. In a recent publication, Hoffer et al usedtion-dependent “thiol stress” observed in these studies is
conceptually similar to the “substrate stress” hypothesis a highly sensitive gas chromatography mass spectrometry
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Fig. 10. Ratio of protein-bound aminothiols to available plasma thiols
in healthy subjects ( ) and hemodialysis patients before () and after
() dialysis. N	 5 for healthy subjects, N	 6 for hemodialysis patients
*P 
 0.002 vs. before hemodialysis.
tended to be more oxidized than glutathione, with other
plasma aminothiols being intermediate. As previously
noted, glutathione is largely an intracellular antioxidant
and plasma glutathione levels likely reflect cellular secre-
tion of this antioxidant. Plasma cysteine is derived both
from the metabolism of glutathione and from the trans-
sulfuration of homocysteine, while cysteinylglycine is
predominantly a metabolic product of the degradation
of glutathione. Thus, while the redox status of plasma
glutathione would be a response to both intracellular
and extracellular oxidative processes, the redox status of
cysteine and cysteinylglycine would be a more accurate
reflection of extracellular oxidative status [43]. Further-
more, because the thiols of both cysteine and cysteinyl-
glycine have lower pK values, they more readily undergo
auto-oxidation at physiologic pH.
An interesting finding in the present study is that the
ratio of free to protein-bound cysteine and homocysteineFig. 9. Comparison of total plasma aminothiol concentrations and their
respective protein-bound concentration in healthy subjects () and are higher before dialysis in uremic subjects compared
uremic patients before () and after () dialysis. N	 10 in each group. to healthy subjects. A potential explanation for this find-
Slopes calculated for all samples.
ing is that higher levels of plasma cysteine and homocys-
teine seen in uremic subjects leads to a relative saturation
of protein binding with a subsequent increase in free
fractions. Support for this concept comes from previousmethod for measuring plasma-reduced homocysteine
concentrations in hemodialysis patients [55]. These au- work by Mansoor, Ueland, and Svardal, who demon-
strated relative saturability of protein-bound homocys-thors demonstrated elevated plasma-reduced homocys-
teine levels in dialysis patients that were significantly teine as plasma total homocysteine levels approach 140
mol/L in patients with cobalamin deficiency [60]. Inrelated to plasma homocysteine concentration. Both re-
duced and total plasma homocysteine concentrations uremic patients, an additional potential explanation is
that there may be a decrease in available plasma proteinwere lowered by the hemodialysis procedure.
A notable finding in the present study is that in uremic thiol binding sites as a function of oxidative stress [15].
Reactive carbonyl compounds, which have been demon-subjects, the redox state of the various plasma aminothi-
ols is not in equilibrium. Specifically, the oxidized to re- strated to accumulate in uremia, also may compete with
plasma aminothiols for plasma protein-associated thiolduced ratio of free homocysteine is greater than cysteine,
which is greater than cysteinylglycine, which is greater binding. Also of interest, the hemodialysis procedure
results in a marked decrease in the ratio of free to pro-than glutathione. That the redox state of the plasma
aminothiols is not in equilibrium is not surprising given tein-bound cysteine, cysteinylglycine and homocysteine
(compared to before dialysis levels) in uremic subjects.that they likely derive from different sources (Fig. 1).
Of note, Jones et al recently performed a similar analysis This finding is consistent with the relatively greater clear-
ance of unbound compared to protein-bound solute re-in healthy subjects and also demonstrated that cysteine
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prevalent cardiovascular disease in hemodialysis. Kidney Intlated to pore size with high flux hemodialysis mem-
56:1078–1083, 1999
branes. 13. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, et al: Glu-
tathione antioxidant system as a marker of oxidative stress in
chronic renal failure. Free Radical Biol Med 21:845–853, 1996Conclusion
14. Nguyen-Khoa T, Massy ZA, Pascal De Bandt J, et al: Oxidative
This study demonstrates that both the plasma concen- stress and haemodialysis: Role of inflammation and duration of
dialysis treatment. Nephrol Dial Transplant 16:335–340, 2001tration and the redox status of aminothiols are altered in
15. Himmelfarb J, McMonagle E, McMenamin E: Plasma proteinuremia and improved with the hemodialysis procedure. thiol oxidation and carbonyl formation in chronic renal failure.
Plasma aminothiol oxidation in uremia is part of a more Kidney Int 58:2571–2578, 2000
16. Deneke SM: Thiol-based antioxidants. Curr Top Cell Regul 36:151–generalized “thiol stress,” which is also manifested by
180, 2000plasma protein thiol oxidation [15]. Potential vascular 17. Munday R: Toxicity of thiols and disulphides: Involvement of
toxicity of oxidant stress in general and aminothiol oxida- free-radical species. Free Rad Biol Med 7:659–673, 1989
18. Bostom AG, Shemin D, Lapane KL, et al: Hyperhomocysteinemia,tion in particular in chronic hemodialysis patients sug-
hyperfibrinogenemia and lipoprotein (a) excess in maintenancegests that amelioration of thiol stress in chronic hemodi- dialysis patients: A matched case-control study. Atherosclerosis
alysis patients may have beneficial cardiovascular effects. 125:91–101, 1996
19. Bostom AG, Shemin D, Verhoef P, et al: Elevated fasting totalFurther research is needed to examine the safety and
plasma homocysteine levels and cardiovascular disease outcomes
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rosis Thromb Vasc Biol 17:2554–2558, 1997plasma thiol oxidative stress status in chronic hemodialy-
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21. Hultberg B, Andersson A, Arnadottir M: Reduced, free, andACKNOWLEDGMENT
total fractions of homocysteine and other thiol compounds in
We gratefully acknowledge the secretarial assistance of Ms. Karen plasma from patients with renal failure. Nephron 70:62–67, 1995
Kinne. 22. Soria C, Chadefaux B, Coude M, et al: Concentrations of total
homocysteine in plasma in chronic renal failure. Clin Chem
Reprint requests to Jonathan Himmelfarb, M.D., Division of Ne- 36:2137–2138, 1990
phrology and Renal Transplantation, Maine Medical Center, 22 Bram- 23. Suliman ME, Divino-Filho JC, Barany P, et al: Effects of high-
hall Street, Portland, Maine 04102,USA. dose folic acid and pyridoxine on plasma and erythrocyte sulfur
amino acids in hemodialysis patients. J Am Soc Nephrol 10:1287–E-mail: himmej@mmc.org
1296, 1999
24. Suliman ME, Divino-Filho JC, Barany P, et al: Effects of methio-
REFERENCES nine loading on plasma and erythrocyte sulphur amino acids and
sulph-hydryls before and after co-factor supplementation in hae-1. Hasselwander O, Young IS: Oxidative stress in chronic renal
modialysis patients. Nephrol Dial Transplant 16:102–110, 2001failure. Free Rad Res 29:1–11, 1998 25. Suliman ME, Anderstam B, Lindholm B, Bergstrom J: Total,2. Galli F, Canestrari F, Bellomo G: Physiopathology of the oxida- free, and protein-bound sulphur amino acids in uraemic patients.tive stress and its implications in uremia and dialysis. Contrib Nephrol Dial Transplant 12:2332–2338, 1997
Nephrol 127:1–31, 1999 26. Robinson K, Gupta A, Dennis V, et al: Hyperhomocysteinemia
3. Schettler V, Weiland E, Methe H, et al: Oxidative stress during confers an independent increased risk of atherosclerosis in end-
dialysis: Effect on free radical scavenging enzyme (FRSE) activities stage renal disease and is closely linked to plasma folate and pyri-
and glutathione (GSH) concentration in granulocytes. Nephrol doxine concentrations. Circulation 94:2743–2748, 1996
Dial Transplant 13:2588–2593, 1998 27. Moustapha A, Naso A, Nahlawi M, et al: Prospective study of
4. Tetta C, Biasioli S, Schiavon R, et al: An overview of haemodial- hyperhomocysteinemia as an adverse cardiovascular risk factor in
ysis and oxidative stress. Blood Purif 17:118–126, 1999 end-stage renal disease. Circulation 97:138–141, 1998
5. Stenvinkel P, Holmberg I, Heimburger O, Diczfalusy U: A 28. Hajjar KA: Homocysteine: A sulph’rous fire. J Clin Invest 107:663–
study of plasmalogen as an index of oxidative stress in patients 664, 2001
with chronic renal failure: Evidence of increased oxidative stress 29. Loscalzo J: The oxidant stress of hyperhomocysteinemia. J Clin
in malnourished patients. Nephrol Dial Transplant 13:2594–2600, Invest 98:5–7, 1996
1998 30. Heinecke JW, Rosen H, Suzuki LA, Chait A: The role of sulfur-
6. Loughrey CM, Young IS, Lightbody JH, et al: Oxidative stress containing amino acids in superoxide production and modification
in haemodialysis. Q J Med 87:679–683, 1994 of low density lipoprotein by arterial smooth muscle cells. J Biol
7. Witko-Sarsat V, Freidlander M, Capeillere-Blandin C, et al: Chem 262:10098–10103, 1987
Advanced oxidation protein products as a novel marker of oxida- 31. Tsai JC, Perrella MA, Yoshizumi M, et al: Promotion of vascular
tive stress in uremia. Kidney Int 49:1304–1313, 1996 smooth muscle cell growth by homocysteine: A link to atheroscle-
8. Roselaar SE, Nazhat JB, Winyard PG, et al: Detection of oxi- rosis. Proc Natl Acad Sci USA 91:6369–6373, 1994
dants in uremic plasma by electron spin resonance spectroscopy. 32. D’Angelo A, Selhub J: Homocysteine and thrombotic disease.
Kidney Int 48:199–206, 1995 Blood 90:1–11, 1997
9. Becker BN, Himmelfarb J, Henrich WL, Hakim RM: Reassessing 33. Hofmann MA, Lalla E, Lu Y: Hyperhomocysteinemia enhances
the cardiac risk profile in chronic hemodialysis patients: A hypothe- vascular inflammation and accelerates atherosclerosis in a murine
sis on the role of oxidant stress and other non-traditional cardiac model. J Clin Invest 107:675–683, 2001
risk factors. J Am Soc Nephrol 8:475–486, 1997 34. Lentz SR, Sorey CG Piegors DJ, et al: Vascular dysfunction in
10. Maggi E, Bellazzi R, Falaschi F, et al: Enhanced LDL oxidation monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest
in uremic patients: An additional mechanism for accelerated ath- 98:24–29, 1996
erosclerosis? Kidney Int 45:876–883, 1994 35. McCully KS: Vascular pathology of homocysteinemia: Implica-
11. Boaz M, Green M, Smetana S: Oxidative stress and cardiovascular tions for the pathogenesis of arteriosclerosis. Am J Pathol 56:111–
disease in hemodialysis. Clin Nephrol 55:93–100, 2001 128, 1969
36. Graham LM, Daly LE, Refsum HMet al: Plasma homocysteine as12. Boaz M, Mataz Z, Biro A, et al: Serum malondialdehyde and
Himmelfarb et al: Aminothiol oxidation in uremia716
a risk factor for vascular disease: The European Concerted Action 50. Hogg N: The effect of cysteine on the auto-oxidation of homocys-
teine. Free Radical Biol Med 27:28–33, 1999Project. JAMA 277:1775–1781, 1997
51. Heinecke JW, Kawamura M, Suzuki L, Chait A: Oxidation of37. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG: A quanti-
low density lipoprotein by thiols: Superoxide-dependent and -inde-tative assessment of plasma homocysteine as a risk factor for vascu-
pendent mechanisms. J Lipid Res 34:2051–2061, 1993lar disease. JAMA 274:1049–1057, 1995
52. Andersson A, Lindgren A, Arnadottir M, et al: Thiols as a38. Nygard O, Nordrenhaug JE, Refsum H, et al: Plasma homocys-
measure of plasma redox status in healthy subjects and in patientsteine levels and mortality in patients with coronary artery disease.
with renal or liver failure. Clin Chem 45:1084–1086, 1999N Engl J Med 337:230–236, 1997
53. Ross EA, Koo LC, Moberly JB: Low whole blood and erythrocyte39. Kugiyama K, Ohgushi M, Motoyama T, et al: Intracoronary infu-
levels of glutathione in hemodialysis and peritoneal dialysis pa-sion of reduced glutathione improves endothelial vasomotor re-
tients. Am J Kidney Dis 30:489–494, 1997sponse to acetylcholine in human coronary circulation. Circulation
54. Constagliola C, Romano L, Sorice P, Di Benedetto A: Anemia97:2299–2301, 1998
and chronic renal failure: The possible role of oxidative state of40. Morrison JA, Jacobsen DW, Sprecher DL, et al: Serum glutathi-
glutathione. Nephron 52:11–14, 1989one in adolescent males predicts parental coronary heart disease.
55. Hoffer LJ, Robitaille L, Elian KM, et al: Plasma reduced homo-Circulation 100:2244–2247, 1999
cysteine concentrations are increased in end-stage renal disease.41. Lapenna D, de Gioia S, Ciofani G, et al: Glutathione-related
Kidney Int 59:372–377, 2001antioxidant defenses in human atherosclerotic plaques. Circulation
56. Ueland PM, Mansoor MA, Guttormsen AB, et al: Reduced,97:1930–1934, 1998
oxidized and protein-bound forms of homocysteine and other42. Mansoor MA, Svardal AM, Ueland PM: Determination of the
aminothiols in plasma comprise the redox thiol status—A possiblein vivo redox status of cysteine, cysteinylglycine, homocysteine
element of the extracellular antioxidant defense system. J Nutrand glutathione in human plasma. Annal Biochem 200:218–229,
126:1281S–1284S, 19961992 57. Mansoor MA, Guttormsen AB, Fiskerstrand T, et al: Redox43. Jones DP, Carlson JL, Mody VC, et al: Redox state of glutathione status and protein binding of plasma aminothiols during the tran-in human plasma. Free Radical Biol Med 28:625–635, 2000 sient hyperhomocysteinemia that follows homocysteine adminis-
44. Halliwell B, Gutteridge JMC: The antioxidants of human extra- tration. Clin Chem 39:980–985, 1993
cellular fluids. Arch Biochem Biophys 280:1–8, 1990 58. Mansoor MA, Ueland PM, Aarsland A, Svardal AM: Redox
45. Foley RN, Parfrey PS, Sarnak MJ: Epidemiology of cardiovascu- status and protein binding of plasma homocysteine and other
lar disease in chronic renal disease. J Am Soc Nephrol 9(Suppl): aminothiols in patients with homocystinuria. Metabolism 42:1481–
S16–S23, 1998 1485, 1993
46. Cheung AK, Sarnak MJ, Yan G, et al: Atherosclerotic cardiovas- 59. Mansoor MA, Svardal AM, Schneede J, Ueland PM: Dynamic
cular disease risks in chronic hemodialysis patients. Kidney Int relation between reduced, oxidized and protein-bound homocys-
58:353–362, 2000 teine and other thiol components in plasma during methionine
47. Selhub J: Homocysteine metabolism. Ann Rev Nutr 19:217–246, loading in healthy men. Clin Chem 38:1316–1321, 1992
1999 60. Mansoor MA, Ueland PM, Svardal AM: Redox status and pro-
48. Mills BJ, Weiss MM, Lang CA, et al: Blood glutathione and tein binding of plasma homocysteine and other aminothiols in
cysteine changes in cardiovascular disease. J Lab Clin Med patients with hyperhomocysteinemia due to cobalamin deficiency.
135:396–401, 2000 Am J Clin Nutr 59:631–635, 1994
49. Muniz P, Saez P, Iradi A, et al: Differences between cysteine and 61. Baynes JW, Thorpe SR: Role of oxidative stress in diabetic compli-
homocysteine in the induction of deoxyribose degradation and cations: A new perspective on an old paradigm. Diabetes 48:1–9,
1999DNA damage. Free Radical Biol Med 30:354–362, 2001
